(USPH) US Physicalrapy - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US90337L1089
Stock: Physical Therapy, Injury Prevention, Rehabilitation, Ergonomic Assessment
Total Rating 39
Risk 86
Buy Signal -0.02
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.35% |
| Yield on Cost 5y | 1.44% |
| Yield CAGR 5y | 5.37% |
| Payout Consistency | 92.5% |
| Payout Ratio | 92.3% |
| Risk 5d forecast | |
|---|---|
| Volatility | 31.1% |
| Relative Tail Risk | -7.63% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.06 |
| Alpha | -13.87 |
| Character TTM | |
|---|---|
| Beta | 0.781 |
| Beta Downside | 0.834 |
| Drawdowns 3y | |
|---|---|
| Max DD | 45.32% |
| CAGR/Max DD | -0.06 |
Description: USPH US Physicalrapy January 15, 2026
U.S. Physical Therapy, Inc. (NYSE: USPH) runs a network of outpatient physical-therapy clinics and delivers industrial injury-prevention services. Its two operating segments are (1) Physical Therapy Operations, which treats orthopedic, sports-related, neurological and post-surgical conditions, and (2) Industrial Injury Prevention Services, which provides on-site rehabilitation, ergonomic assessments, functional-capacity evaluations and performance-optimization programs for Fortune 500 firms, insurers and contractors.
Key performance indicators from the most recent quarter show revenue growth of roughly 8 % year-over-year, driven by a 12 % increase in same-store sales and a 15 % rise in contract-based industrial services. The outpatient segment benefits from macro-drivers such as the aging U.S. population (the 65-plus cohort is projected to reach 22 % of the population by 2035) and a steady rise in Medicare Part B reimbursement rates, while the industrial segment is buoyed by heightened corporate focus on workplace safety and the expansion of employer-sponsored health-benefit programs.
For a deeper quantitative assessment of USPH’s valuation dynamics, you might find ValueRay’s detailed analyst toolkit worth exploring.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 33.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -2.40 > 1.0 |
| NWC/Revenue: 3.53% < 20% (prev 13.87%; Δ -10.34% < -1%) |
| CFO/TA 0.06 > 3% & CFO 69.5m > Net Income 33.4m |
| Net Debt (277.3m) to EBITDA (113.8m): 2.44 < 3 |
| Current Ratio: 1.20 > 1.5 & < 3 |
| Outstanding Shares: last quarter (15.2m) vs 12m ago 0.84% < -2% |
| Gross Margin: 21.67% > 18% (prev 0.19%; Δ 2148 % > 0.5%) |
| Asset Turnover: 59.42% > 50% (prev 62.74%; Δ -3.32% > 0%) |
| Interest Coverage Ratio: 9.86 > 6 (EBITDA TTM 113.8m / Interest Expense TTM 9.16m) |
Altman Z'' 1.93
| A: 0.02 (Total Current Assets 138.4m - Total Current Liabilities 115.1m) / Total Assets 1.20b |
| B: 0.20 (Retained Earnings 237.3m / Total Assets 1.20b) |
| C: 0.08 (EBIT TTM 90.3m / Avg Total Assets 1.11b) |
| D: 0.58 (Book Value of Equity 238.4m / Total Liabilities 413.8m) |
| Altman-Z'' Score: 1.93 = BBB |
Beneish M -2.97
| DSRI: 1.16 (Receivables 91.3m/77.1m, Revenue 661.2m/645.7m) |
| GMI: 0.87 (GM 21.67% / 18.88%) |
| AQI: 1.10 (AQ_t 0.74 / AQ_t-1 0.67) |
| SGI: 1.02 (Revenue 661.2m / 645.7m) |
| TATA: -0.03 (NI 33.4m - CFO 69.5m) / TA 1.20b) |
| Beneish M-Score: -2.97 (Cap -4..+1) = A |
What is the price of USPH shares?
As of February 08, 2026, the stock is trading at USD 85.58 with a total of 158,429 shares traded.
Over the past week, the price has changed by +2.04%, over one month by +5.33%, over three months by +11.04% and over the past year by -0.13%.
Over the past week, the price has changed by +2.04%, over one month by +5.33%, over three months by +11.04% and over the past year by -0.13%.
Is USPH a buy, sell or hold?
US Physicalrapy has received a consensus analysts rating of 4.14.
Therefore, it is recommended to buy USPH.
- StrongBuy: 2
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the USPH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 105.3 | 23.1% |
| Analysts Target Price | 105.3 | 23.1% |
| ValueRay Target Price | 92.4 | 8% |
USPH Fundamental Data Overview February 03, 2026
P/E Trailing = 34.657
P/E Forward = 29.7619
P/S = 1.6981
P/B = 2.4867
P/EG = 2.9733
Revenue TTM = 661.2m USD
EBIT TTM = 90.3m USD
EBITDA TTM = 113.8m USD
Long Term Debt = 151.5m USD (from longTermDebt, last quarter)
Short Term Debt = 50.8m USD (from shortTermDebt, last quarter)
Debt = 308.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 277.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.55b USD (1.28b + Debt 308.4m - CCE 31.1m)
Interest Coverage Ratio = 9.86 (Ebit TTM 90.3m / Interest Expense TTM 9.16m)
EV/FCF = 27.28x (Enterprise Value 1.55b / FCF TTM 56.9m)
FCF Yield = 3.67% (FCF TTM 56.9m / Enterprise Value 1.55b)
FCF Margin = 8.61% (FCF TTM 56.9m / Revenue TTM 661.2m)
Net Margin = 5.05% (Net Income TTM 33.4m / Revenue TTM 661.2m)
Gross Margin = 21.67% ((Revenue TTM 661.2m - Cost of Revenue TTM 517.9m) / Revenue TTM)
Gross Margin QoQ = 22.48% (prev 25.35%)
Tobins Q-Ratio = 1.30 (Enterprise Value 1.55b / Total Assets 1.20b)
Interest Expense / Debt = 0.78% (Interest Expense 2.41m / Debt 308.4m)
Taxrate = 22.88% (5.23m / 22.9m)
NOPAT = 69.7m (EBIT 90.3m * (1 - 22.88%))
Current Ratio = 1.20 (Total Current Assets 138.4m / Total Current Liabilities 115.1m)
Debt / Equity = 0.61 (Debt 308.4m / totalStockholderEquity, last quarter 503.6m)
Debt / EBITDA = 2.44 (Net Debt 277.3m / EBITDA 113.8m)
Debt / FCF = 4.87 (Net Debt 277.3m / FCF TTM 56.9m)
Total Stockholder Equity = 497.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.00% (Net Income 33.4m / Total Assets 1.20b)
RoE = 6.71% (Net Income TTM 33.4m / Total Stockholder Equity 497.6m)
RoCE = 13.92% (EBIT 90.3m / Capital Employed (Equity 497.6m + L.T.Debt 151.5m))
RoIC = 10.59% (NOPAT 69.7m / Invested Capital 657.7m)
WACC = 7.20% (E(1.28b)/V(1.58b) * Re(8.79%) + D(308.4m)/V(1.58b) * Rd(0.78%) * (1-Tc(0.23)))
Discount Rate = 8.79% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.72%
[DCF Debug] Terminal Value 80.94% ; FCFF base≈63.6m ; Y1≈62.6m ; Y5≈64.4m
Fair Price DCF = 70.27 (EV 1.35b - Net Debt 277.3m = Equity 1.07b / Shares 15.2m; r=7.20% [WACC]; 5y FCF grow -2.35% → 2.90% )
EPS Correlation: -21.95 | EPS CAGR: -2.29% | SUE: -0.11 | # QB: 0
Revenue Correlation: 88.00 | Revenue CAGR: 6.43% | SUE: -2.29 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.56 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=3
EPS next Year (2026-12-31): EPS=2.99 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=+13.6% | Growth Revenue=+6.2%
P/E Forward = 29.7619
P/S = 1.6981
P/B = 2.4867
P/EG = 2.9733
Revenue TTM = 661.2m USD
EBIT TTM = 90.3m USD
EBITDA TTM = 113.8m USD
Long Term Debt = 151.5m USD (from longTermDebt, last quarter)
Short Term Debt = 50.8m USD (from shortTermDebt, last quarter)
Debt = 308.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 277.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.55b USD (1.28b + Debt 308.4m - CCE 31.1m)
Interest Coverage Ratio = 9.86 (Ebit TTM 90.3m / Interest Expense TTM 9.16m)
EV/FCF = 27.28x (Enterprise Value 1.55b / FCF TTM 56.9m)
FCF Yield = 3.67% (FCF TTM 56.9m / Enterprise Value 1.55b)
FCF Margin = 8.61% (FCF TTM 56.9m / Revenue TTM 661.2m)
Net Margin = 5.05% (Net Income TTM 33.4m / Revenue TTM 661.2m)
Gross Margin = 21.67% ((Revenue TTM 661.2m - Cost of Revenue TTM 517.9m) / Revenue TTM)
Gross Margin QoQ = 22.48% (prev 25.35%)
Tobins Q-Ratio = 1.30 (Enterprise Value 1.55b / Total Assets 1.20b)
Interest Expense / Debt = 0.78% (Interest Expense 2.41m / Debt 308.4m)
Taxrate = 22.88% (5.23m / 22.9m)
NOPAT = 69.7m (EBIT 90.3m * (1 - 22.88%))
Current Ratio = 1.20 (Total Current Assets 138.4m / Total Current Liabilities 115.1m)
Debt / Equity = 0.61 (Debt 308.4m / totalStockholderEquity, last quarter 503.6m)
Debt / EBITDA = 2.44 (Net Debt 277.3m / EBITDA 113.8m)
Debt / FCF = 4.87 (Net Debt 277.3m / FCF TTM 56.9m)
Total Stockholder Equity = 497.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.00% (Net Income 33.4m / Total Assets 1.20b)
RoE = 6.71% (Net Income TTM 33.4m / Total Stockholder Equity 497.6m)
RoCE = 13.92% (EBIT 90.3m / Capital Employed (Equity 497.6m + L.T.Debt 151.5m))
RoIC = 10.59% (NOPAT 69.7m / Invested Capital 657.7m)
WACC = 7.20% (E(1.28b)/V(1.58b) * Re(8.79%) + D(308.4m)/V(1.58b) * Rd(0.78%) * (1-Tc(0.23)))
Discount Rate = 8.79% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.72%
[DCF Debug] Terminal Value 80.94% ; FCFF base≈63.6m ; Y1≈62.6m ; Y5≈64.4m
Fair Price DCF = 70.27 (EV 1.35b - Net Debt 277.3m = Equity 1.07b / Shares 15.2m; r=7.20% [WACC]; 5y FCF grow -2.35% → 2.90% )
EPS Correlation: -21.95 | EPS CAGR: -2.29% | SUE: -0.11 | # QB: 0
Revenue Correlation: 88.00 | Revenue CAGR: 6.43% | SUE: -2.29 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.56 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=3
EPS next Year (2026-12-31): EPS=2.99 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=+13.6% | Growth Revenue=+6.2%